Living Cell Technologies Ltd. Enrolls First Patients in DIABECELL(R) Argentina Trial
Published: Jun 27, 2011
LCT announced last month approval to enrol eight patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia into the trial.
The first two patients have commenced the pre-transplant phase of the trial which will establish a stable baseline from which to compare the post-treatment data to, and determine whether the endpoints have been reached. The two patients are each scheduled to receive the first of their two implants in August at the dose of 5,000 Islet Equivalents per kg of body weight (IEQ/kg), followed three months later by their second implant at the same dose. Both patients have pre-existing severe hypoglycaemia and long term complications from their diabetes.
Dr Adrian Abalovich, MD, principal investigator of the Argentinean trial, said: "Unstable diabetes has a significant impact on the health of patients and can cause long term complications. We are very pleased to be in a position to trial DIABECELL, which will hopefully provide a new treatment option for patients in the future."
Professor Bob Elliott, LCT's Medical Director, added: "This is an important milestone for LCT and for people with unstable Type 1 diabetes. This is the third jurisdiction in which DIABECELL will be trialled and the results will contribute to the growing body of evidence to support the need for an alternative treatment to Type 1 diabetes."
The Argentinean trial approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first twelve patients to receive DIABECELL implants in LCTs Phase II trial in New Zealand, as well as favourable two-year follow up data from its Phase I/IIa clinical trial in Russia. LCT has recently announced plans for collaborative development of DIABECELL in Asia following the strategic investments made in LCT by ASK in China and Otsuka in Japan.
DIABECELL is LCT's treatment in development to normalise the lives of people with insulin-dependent diabetes. DIABECELL comprises encapsulated porcine insulin-producing cells (islets) that are implanted into the abdomen of patients using a simple laparoscopic procedure, and work by self-regulating and efficiently secreting insulin in the patient's body.
LCT's breakthrough proprietary encapsulation technology, IMMUPEL(tm), means that patients receiving DIABECELL treatment do not require immunosuppression after implantation.
For further information: www.lctglobal.com
At the Company:
Prof Bob Elliott
Mob: +64 27 292 4177
Tel:+64 9 276 2690
Media and investor enquiries:
Tel: +61 3 9866 4722
Mobile: +61 417 382 391
About Living Cell Technologies - www. lctglobal.com Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company implants its lead product DIABECELL, microencapsulated islet cells, in an effort to address the shortcomings of existing insulin therapy. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells, NTCELL, which delivers beneficial proteins and neurotrophic factors to the brain. LCT's breakthrough microencapsulation technology, IMMUPEL, enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.
LCT Disclaimer This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.